View in EDS

Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models.

Saved in:
Bibliographic Details
Title: Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models.
Authors: Gruber DR; Pfizer, Inc., Bothell, Washington., Cummins EJ; Pfizer, Inc., Bothell, Washington., Zeng W; Pfizer, Inc., Bothell, Washington., Ulrich M; Pfizer, Inc., Bothell, Washington., Smith K; Pfizer, Inc., Bothell, Washington., Long M; Pfizer, Inc., Bothell, Washington., Spahr K; Pfizer, Inc., Bothell, Washington., Higgins S; Pfizer, Inc., Bothell, Washington., Hinricher K; Pfizer, Inc., Bothell, Washington., Langalia A; Pfizer, Inc., Bothell, Washington., Krumm K; Pfizer, Inc., Bothell, Washington., Olson DJ; Pfizer, Inc., Bothell, Washington., Grogan B; Pfizer, Inc., Bothell, Washington., Mazahreh R; Pfizer, Inc., Bothell, Washington., Gupta P; Pfizer, Inc., Bothell, Washington., Burke PJ; Pfizer, Inc., Bothell, Washington., Smith A; Pfizer, Inc., Bothell, Washington., Senter PD; Pfizer, Inc., Bothell, Washington., Gardai SJ; Pfizer, Inc., Bothell, Washington., Hill AG; Pfizer, Inc., Bothell, Washington., Gray EE; Pfizer, Inc., Bothell, Washington.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2026 Mar 02; Vol. 25 (3), pp. 457-468.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41159384
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gruber+DR%22">Gruber DR</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Cummins+EJ%22">Cummins EJ</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Zeng+W%22">Zeng W</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Ulrich+M%22">Ulrich M</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Smith+K%22">Smith K</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Long+M%22">Long M</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Spahr+K%22">Spahr K</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Higgins+S%22">Higgins S</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Hinricher+K%22">Hinricher K</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Langalia+A%22">Langalia A</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Krumm+K%22">Krumm K</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Olson+DJ%22">Olson DJ</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Grogan+B%22">Grogan B</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Mazahreh+R%22">Mazahreh R</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Gupta+P%22">Gupta P</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Burke+PJ%22">Burke PJ</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Smith+A%22">Smith A</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Senter+PD%22">Senter PD</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Gardai+SJ%22">Gardai SJ</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Hill+AG%22">Hill AG</searchLink>; Pfizer, Inc., Bothell, Washington.<br /><searchLink fieldCode="AU" term="%22Gray+EE%22">Gray EE</searchLink>; Pfizer, Inc., Bothell, Washington.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2026 Mar 02; Vol. 25 (3), pp. 457-468.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41159384
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-25-0108
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 457
    Titles:
      – TitleFull: Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gruber DR
      – PersonEntity:
          Name:
            NameFull: Cummins EJ
      – PersonEntity:
          Name:
            NameFull: Zeng W
      – PersonEntity:
          Name:
            NameFull: Ulrich M
      – PersonEntity:
          Name:
            NameFull: Smith K
      – PersonEntity:
          Name:
            NameFull: Long M
      – PersonEntity:
          Name:
            NameFull: Spahr K
      – PersonEntity:
          Name:
            NameFull: Higgins S
      – PersonEntity:
          Name:
            NameFull: Hinricher K
      – PersonEntity:
          Name:
            NameFull: Langalia A
      – PersonEntity:
          Name:
            NameFull: Krumm K
      – PersonEntity:
          Name:
            NameFull: Olson DJ
      – PersonEntity:
          Name:
            NameFull: Grogan B
      – PersonEntity:
          Name:
            NameFull: Mazahreh R
      – PersonEntity:
          Name:
            NameFull: Gupta P
      – PersonEntity:
          Name:
            NameFull: Burke PJ
      – PersonEntity:
          Name:
            NameFull: Smith A
      – PersonEntity:
          Name:
            NameFull: Senter PD
      – PersonEntity:
          Name:
            NameFull: Gardai SJ
      – PersonEntity:
          Name:
            NameFull: Hill AG
      – PersonEntity:
          Name:
            NameFull: Gray EE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 03
              Text: 2026 Mar 02
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1